Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors bringing the total number of PCCs nominated in 2023 to six.

Simple biomarkers offer early warning of hidden heart risk in childhood cancer survivors

Data from the St. Jude lifetime cohort study (St. Jude LIFE) revealed that two common biomarkers of cardiac function and damage could better predict cardiomyopathy within five

January 12, 2024

Researchers downplay study that found a link between semaglutide and mental health

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 24, 2024

Atropos Health Partners, Janssen Partner to Accelerate Clinical Trials with RWD

What You Should Know: Atropos Health, a pioneer in evidence-based healthcare known for its Green Button Clinical Informatics Consult Service, today announced an agreement with Janssen

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.